Qihai Sui

955 total citations
41 papers, 591 citations indexed

About

Qihai Sui is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Qihai Sui has authored 41 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 23 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Qihai Sui's work include Ferroptosis and cancer prognosis (15 papers), RNA modifications and cancer (14 papers) and Lung Cancer Treatments and Mutations (13 papers). Qihai Sui is often cited by papers focused on Ferroptosis and cancer prognosis (15 papers), RNA modifications and cancer (14 papers) and Lung Cancer Treatments and Mutations (13 papers). Qihai Sui collaborates with scholars based in China, Italy and South Korea. Qihai Sui's co-authors include Cheng Zhan, Jiaqi Liang, Zhengyang Hu, Qun Wang, Zhencong Chen, Yiwei Huang, Ming Li, Mengnan Zhao, Yunyi Bian and Guoshu Bi and has published in prestigious journals such as Nature Communications, Cell Reports and Pharmaceutical Research.

In The Last Decade

Qihai Sui

35 papers receiving 586 citations

Peers

Qihai Sui

PRM

ONCOL

IMMUN

Hanbo Le China

Changwen Jing China

Silei Sui China

Qiaoliang Zhu China

Inés López Spain

Heshu Liu China

Xiangli Jiang China

Javier I. J. Orozco United States

Gabriela Raso United States

Kaikai Zhao China

Hanbo Le China

Qihai Sui

473 ×1.3

143 ×0.6

PRM

437 ×1.8

175 ×0.9

ONCOL

121 ×1.2

IMMUN

Citations per year, relative to Qihai Sui Qihai Sui (= 1×) peers Hanbo Le

Countries citing papers authored by Qihai Sui

Since Specialization

Citations

This map shows the geographic impact of Qihai Sui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qihai Sui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qihai Sui more than expected).

Fields of papers citing papers by Qihai Sui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qihai Sui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qihai Sui. The network helps show where Qihai Sui may publish in the future.

Co-authorship network of co-authors of Qihai Sui

This figure shows the co-authorship network connecting the top 25 collaborators of Qihai Sui. A scholar is included among the top collaborators of Qihai Sui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qihai Sui. Qihai Sui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liang, Jiaqi, Guoshu Bi, Xiaolong Huang, et al.. (2025). CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer. Cancer Communications. 45(11). 1547–1578.

Bian, Yunyi, Guangyao Shan, Guoshu Bi, et al.. (2025). Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. Nature Communications. 16(1). 9923–9923.

Hu, Zhengyang, Xing Jin, Qihai Sui, et al.. (2025). Analysis of the Clinicopathological Characteristics, Genetic Phenotypes, and Prognostics of Primary Pulmonary and Bronchial Adenoid Cystic Carcinoma. Thoracic Cancer. 16(2). e15526–e15526.

Yin, Jiacheng, et al.. (2025). HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules. World Journal of Surgical Oncology. 23(1). 304–304.

Sui, Qihai, et al.. (2024). The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors. Pharmaceutical Research. 41(11). 2143–2159. 3 indexed citations

Liang, Jiaqi, Guoshu Bi, Qihai Sui, et al.. (2024). Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Reports. 43(2). 113771–113771. 20 indexed citations

Hu, Zhengyang, Qihai Sui, Xing Jin, et al.. (2024). IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma. Journal of Experimental & Clinical Cancer Research. 43(1). 63–63. 48 indexed citations

Bian, Yunyi, Guangyao Shan, Guoshu Bi, et al.. (2024). Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. Redox Biology. 77. 103361–103361. 15 indexed citations

Hu, Zhengyang, Xing Jin, Weifeng Hong, et al.. (2023). Dissecting the single-cell transcriptome network of macrophage and identifies a signature to predict prognosis in lung adenocarcinoma. Cellular Oncology. 46(5). 1351–1368. 13 indexed citations

10.

Sui, Qihai, Zhengyang Hu, Jiaqi Liang, et al.. (2023). Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma. Cancer Letters. 581. 216497–216497. 14 indexed citations

11.

Sui, Qihai, Zhengyang Hu, Xing Jin, et al.. (2023). The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data. Cell & Bioscience. 13(1). 103–103. 7 indexed citations

12.

Liang, Jiaqi, Guangyin Zhao, Yunyi Bian, et al.. (2023). HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway. PeerJ. 11. e14996–e14996. 6 indexed citations

13.

Bian, Yunyi, Guoshu Bi, Guangyao Shan, et al.. (2023). Identification of the relationship between single-cell N6-methyladenosine regulators and the infiltrating immune cells in esophageal carcinoma. Heliyon. 9(8). e18132–e18132. 3 indexed citations

14.

Jin, Xing, Zhengyang Hu, Qihai Sui, et al.. (2022). A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma. Journal of Immunology Research. 2022. 1–26. 7 indexed citations

15.

Zhao, Mengnan, Ming Li, Yuansheng Zheng, et al.. (2022). Identification and analysis of a prognostic ferroptosis and iron-metabolism signature for esophageal squamous cell carcinoma. Journal of Cancer. 13(5). 1611–1622. 29 indexed citations

16.

Sui, Qihai, Jiaqi Liang, Zhengyang Hu, et al.. (2021). The clinical prognostic factors of patients with stage IB lung adenocarcinoma. Translational Cancer Research. 10(11). 4727–4738. 6 indexed citations

17.

Hu, Zhengyang, Guoshu Bi, Qihai Sui, et al.. (2020). Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma. International Immunopharmacology. 88. 106910–106910. 7 indexed citations

18.

Chen, Zhencong, Mengnan Zhao, Ming Li, et al.. (2020). Identification of differentially expressed genes in lung adenocarcinoma cells using single-cell RNA sequencing not detected using traditional RNA sequencing and microarray. Laboratory Investigation. 100(10). 1318–1329. 23 indexed citations

19.

Liang, Jiaqi, Ming Li, Qihai Sui, et al.. (2020). Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. Translational Lung Cancer Research. 9(4). 1302–1323. 23 indexed citations

20.

Xi, Junjie, Zhengyang Hu, Jiaqi Liang, et al.. (2020). Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I–IIIA non-small cell lung cancer: a propensity-matched analysis. Journal of Thoracic Disease. 12(6). 3043–3056. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact